Navigation Links
Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
Date:3/10/2010

CORAL GABLES, Fla., March 10 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced that Patrick J. McEnany, Catalyst's Chief Executive Officer, will be making a presentation at the BioNetwork East 2010 Conference to be held March 15th through March 17th at the Eden Roc Resort and Spa on Miami Beach.  Catalyst will present a Corporate Overview, including its development plans for CPP-109 and CPP-115. Further, the Company reported that its presentation materials from the conference will be posted on March 16th on the Company's website, www.catalystpharma.com, under "Events and Presentations."

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. The Company has obtained from Brookhaven National Laboratory an exclusive license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also in-licensed worldwide rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. CPP-109, Catalyst's version of vigabatrin, has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction.  Catalyst has also recently in-licensed worldwide rights to another patented drug, CPP-115, from Northwestern University. The Company intends to pursue development of CPP-115 for several indications, including epilepsy and drug addiction.  For more information about the Company, go to www.catalystpharma.com.

SOURCE Catalyst Pharmaceutical Partners, Inc.

Back to top

RELATED LINKS
http://www.catalystpharma.com

'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Research and Markets has announced the ... Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis ... ... Aids Market Sales Volume, Company Analysis and Forecast to 2022 ... industry. The growing prevalence of hearing impairment coupled ...
(Date:1/20/2017)... , January 20, 2017 Stock-Callers.com today ... SGYP ), Novo Nordisk A/S (NYSE: ... and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX ). ... Thursday, January 19 th , 2017, finishing near its session ... Index dropped over 0.7%, while shares of health care companies ...
(Date:1/20/2017)... BUFFALO, N.Y. , Jan. 20, 2017 /PRNewswire/ ... health programs, has announced the launch of an ... to new guidelines on opioids and helps stem ... Opioids are often prescribed to treat chronic non-cancer ... disease) despite serious risks and lack of evidence ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals ... of a simple test will take days to arrive to the end customer, having ... direct access to their lab tests, bypassing the cost and delay of traditional means. ...
(Date:1/21/2017)... ... January 21, 2017 , ... "ProDOF is the perfect set of tools for video ... subject in a scene," said Christina Austin - CEO of Pixel Film Studios. , ... Easily create the illusion of a DSLR racking focus from one area into the next. ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni Association ... of events for its annual meeting “Coming Home 2017,” an activity-packed weekend of ... 2017” will be held on Friday January 27 through Sunday, January 29, 2017 ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... In the ... when individuals experience the freedom of recovery, they often feel shame for having struggled ... post-traumatic stress disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating ...
(Date:1/20/2017)... MD (PRWEB) , ... January 20, 2017 , ... A ... to donate items they no longer use or need, from clothes to couches to ... any unwanted items and take them to the nearest Goodwill donation center through February ...
Breaking Medicine News(10 mins):